Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Bone marrow transplantation allows the doctor to give higher doses of chemotherapy and kill more cancer cells. PURPOSE: Phase II trial to compare the effectiveness of combination chemotherapy with or without donor bone marrow transplantation in treating infants who have previously untreated acute lymphobla... Read More
Gender:
ALL
Ages:
1 year and below
Trial Updated:
02/18/2014
Locations: MBCCOP - LSU Health Sciences Center, New Orleans, Louisiana
Conditions: Leukemia
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Terminated
This study will compare treatment with 3 courses of high-dose dexamethasone versus treatment with prednisone, for patients recently diagnosed with immune thrombocytopenic purpura (ITP). The primary hypothesis is that patients treated with high-dose dexamethasone will obtain a more durable remission than patients treated with prednisone.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
01/02/2014
Locations: Tulane University, New Orleans, Louisiana
Conditions: Immune Thrombocytopenic Purpura
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have non-Hodgkin's lymphoma or acute lymphocytic leukemia.
Gender:
ALL
Ages:
22 years and below
Trial Updated:
08/19/2013
Locations: MBCCOP - LSU Health Sciences Center, New Orleans, Louisiana +2 locations
Conditions: Leukemia, Lymphoma
Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
Completed
RATIONALE: Denileukin diftitox may be able to deliver cancer-killing substances directly to T-cell lymphoma cells. Dexamethasone may decrease the side effects of denileukin diftitox. PURPOSE: Phase II trial to study the effectiveness of dexamethasone in preventing side effects following treatment with denileukin diftitox in treating patients who have persistent or recurrent T-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2013
Locations: Tulane University School of Medicine, New Orleans, Louisiana
Conditions: Drug/Agent Toxicity by Tissue/Organ, Lymphoma
Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia
Completed
Phase II trial to study the effectiveness of radiation therapy following chemotherapy in treating children with CNS relapse from acute lymphoblastic leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy may kill more cancer cells.
Gender:
ALL
Ages:
20 years and below
Trial Updated:
01/31/2013
Locations: MBCCOP - LSU Medical Center, New Orleans, Louisiana +2 locations
Conditions: Leukemia
Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting
Completed
This is a Phase III trial designed to demonstrate that casopitant (GW679769) plus dexamethasone and ondansetron is more effective in the prevention of vomiting than dexamethasone and ondansetron alone following the administration of moderately emetogenic chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2012
Locations: GSK Investigational Site, Alexandria, Louisiana +2 locations
Conditions: Vomiting, Nausea, Nausea and Vomiting, Chemotherapy-Induced
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
Completed
Subjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2010
Locations: Ochsner Clinic Foundation, New Orleans, Louisiana
Conditions: Multiple Myeloma
A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Terminated
To evaluate the safety and efficacy of lenalidomide (Revlimid ®) in combination with dexamethasone in subjects with relapsed or refractory diffuse large B-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/27/2009
Locations: Southwest Oncology Associates, Lafayette, Louisiana
Conditions: Diffuse Large B-cell Lymphoma